These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24900757)

  • 1. Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies.
    Yu M; Lizarzaburu M; Motani A; Fu Z; Du X; Liu JJ; Jiao X; Lai S; Fan P; Fu A; Liu Q; Murakoshi M; Nara F; Oda K; Okuyama R; Reagan JD; Watanabe N; Yamazaki M; Xiong Y; Zhang Y; Zhuang R; Lin DC; Houze JB; Medina JC; Li L
    ACS Med Chem Lett; 2013 Sep; 4(9):829-34. PubMed ID: 24900757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
    Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S
    ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.
    Guo L; Parker DL; Zang Y; Sweis RF; Liu W; Sherer EC; Buist N; Terebetski J; Kelly T; Bugianesi R; Priest BT; Dingley KH; Li X; Mitelman S; Salituro G; Trujillo ME; Pachanski M; Kirkland M; Powles MA; Eiermann GJ; Feng Y; Shang J; Howard AD; Ujjainwalla F; Sinz CJ; Debenham JS; Edmondson SD; Nargund RP; Hagmann WK; Li D
    ACS Med Chem Lett; 2016 Dec; 7(12):1107-1111. PubMed ID: 27994747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
    Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.
    Lin HV; Efanov AM; Fang X; Beavers LS; Wang X; Wang J; Gonzalez Valcarcel IC; Ma T
    PLoS One; 2016; 11(6):e0157298. PubMed ID: 27322810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling.
    Wang J; Carrillo JJ; Lin HV
    PLoS One; 2016; 11(4):e0154452. PubMed ID: 27104960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function.
    Lin HV; Wang J; Wang J; Li W; Wang X; Alston JT; Thomas MK; Briere DA; Syed SK; Efanov AM
    Mol Metab; 2018 May; 11():205-211. PubMed ID: 29506910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.
    Liu LZ; Ma T; Zhou J; Long Hu Z; Jun Zhang X; Zhen Zhang H; Zeng M; Liu J; Li L; Jiang Y; Zou Z; Wang F; Zhang L; Xu J; Wang J; Xiao F; Fang X; Zou H; Efanov AM; Thomas MK; Lin HV; Chen J
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126857. PubMed ID: 31982234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent.
    Al-Amily IM; Dunér P; Groop L; Salehi A
    Pflugers Arch; 2019 Apr; 471(4):633-645. PubMed ID: 30767071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
    Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations.
    Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2018 May; 36(7):1788-1805. PubMed ID: 28571491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential role of GPR142 in tryptophan-mediated enhancement of insulin secretion in obese and lean mice.
    Ueda Y; Iwakura H; Bando M; Doi A; Ariyasu H; Inaba H; Morita S; Akamizu T
    PLoS One; 2018; 13(6):e0198762. PubMed ID: 29889885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and pharmacological effects of a novel GPR142 antagonist.
    Murakoshi M; Kuwabara H; Nagasaki M; Xiong YM; Reagan JD; Maeda H; Nara F
    J Recept Signal Transduct Res; 2017 Jun; 37(3):290-296. PubMed ID: 27807998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.